



Dr. Guillermo Torre-Amione, MD, PhD, FACC

Research Areas:

- Heart Failure
- Inmunomodulation
- Cardiac Transplant
- B-cell response

Email: gtorre@itesm.mx

Guillermo Torre-Amione received his medical degree from Tecnológico de Monterrey, and earned a PhD in Immunology from the University of Chicago in 1990. He subsequently completed his training in Internal Medicine and Cardiology with subspecialty training in Cardiac Transplantation and Interventional Cardiology at Baylor College of Medicine in Houston. He is certified and re-certified by the Board of Internal Medicine, Cardiology and Consejo Mexicano de Cardiología.

He was the Chief of the Section of Heart Failure and Cardiac Transplantation at the Methodist Hospital in Houston from 1995 to 2010. He became a full professor of Medicine at Weill Cornell Medical College, at The Methodist Hospital in Houston in 2008. During his tenure at The Methodist Hospital he was a member of the board of the Heart and Vascular Center, and established the Cardiac Transplantation research endowment.

After 26 years in the United States, he returned to Mexico to become President of TEC Salud and Professor at the Cardiovascular Medicine Research Group at Medical School. He also maintains an academic appointment at the Methodist Hospital in Houston. Dr. Guillermo Torre-Amione is a Level 3 member of the National Researchers Council. He has published over 170 peer-reviewed articles and has participated in the writing of five books. He was also a member of the editorial board of Methodist DeBakey Cardiovascular Journal, Archivos de Cardiología de México and American College of Cardiology Scientific Session. He has received several awards and recognitions, among those the Scopus Award for the most referenced medical scientist in 2012 in Mexico (nearly to 10,000 cites).

Torre-Amione's Lab conducts research examining the mechanisms of immune activation and inflammation as it relates to myocardial dysfunction in the areas of heart failure and cardiac transplantation. Dr. Torre-Amione and his colleagues have conducted numerous studies that suggest novel immune modulatory therapies for the treatment of heart failure. Dr. Torre-Amione led the first two FDA-approved trials of Celacade with impressive results, and a Phase III trial is underway. Other studies underway in the Heart Failure Research Laboratory are investigating additional immune response pathways that contribute to the progression

of heart failure, particularly the role of B-cells in the progression of fibrosis and pathological hypertrophy.

Most recent publications:

1. Guha A, Nguyen D, Cruz-Solbes AS, Amione-Guerra J, Schutt RC, Bhimaraj A, Trachtenberg BH, Park MH, Graviss EA, Gaber O, Suarez E, Montane E, **Torre-Amione G**, Estep JD. Risk Stratification of Patients With Current Generation Continuous-Flow Left Ventricular Assist Devices Being Bridged to Heart Transplantation. *ASAIO J.* 2018 Mar/Apr;64(2):196-202.
2. Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, **Torre-Amione G**, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? *Eur J Heart Fail.* 2018 Feb;20(2):317-322.
3. Sánchez-Trujillo L, Vázquez-Garza E, Castillo EC, García-Rivas G, **Torre-Amione G**. Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. *Arch Med Res.* 2017 Jan;48(1):1-11.
4. Amione-Guerra J, Cruz-Solbes AS, Gonzalez Bonilla H, Estep JD, Guha A, Bhimaraj A, Suarez EE, Bruckner BA, **Torre-Amione G**, Park MH, Trachtenberg BH. Melding a High-Risk Patient for Continuous Flow Left Ventricular Assist Device into a Low-Risk Patient. *ASAIO J.* 2017 Nov/Dec;63(6):704-712.
5. Segura-Ibarra V, Amione-Guerra J, Cruz-Solbes AS, Cara FE, Iruegas-Nunez DA, Wu S, Youker KA, Bhimaraj A, **Torre-Amione G**, Ferrari M, Karmouty-Quintana H, Guha A, Blanco E. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. *Int J Pharm.* 2017 May 30;524(1-2):257-267.

Webpage: https://www.researchgate.net/profile/Guillermo_Torre